Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Oct 22;41(1):165–177. doi: 10.3892/or.2018.6811

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Wang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 1. — Clinical significance of the expression of RGS5 in ovarian cancer. (A) Expression of RGS5 in endometrioid ovarian carcinoma. (a) Endometrioid ovarian carcinoma cells exhibited cytoplasmic staining for RGS5 (magnification, ×200). (b) Diffuse positive staining for RGS5 in endometrioid ovarian carcinoma (magnification, ×400). (B) Kaplan-Meier progression-free survival curves for the negative expression group (n=45) and the positive expression group (n=57). The difference in the progression-free survival rate between the two groups was statistically significant. ROC curve analysis for each clinicopathological variable and RGS5 expression was performed to evaluate the survival status of patients. (C) RGS5- and CD34-positive blood vessels did not overlap. (D) RGS5- and endoglin-positive blood vessels partially overlapped. (E) RGS5- and endoglin-positive vascular overlap with double immunofluorescence. RGS5, regulator of G-protein signaling 5; ROC, receiver operating characteristics.